Trial Profile
Regression of Fatty Heart by Valsartan Therapy.
Status:
Withdrawn prior to enrolment
Phase of Trial:
Phase IV
Latest Information Update: 09 Nov 2021
Price :
$35
*
At a glance
- Drugs Valsartan (Primary) ; Hydrochlorothiazide
- Indications Metabolic syndrome
- Focus Pharmacodynamics
- 16 Jan 2019 Status changed from recruiting to withdrawn prior to enrolment.
- 18 Sep 2008 New trial record.